EUCTR2004-002453-31-IT进行中（未招募）不适用
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.
ACTELION PHARMACEUTICALS ITALIA0 个研究点目标入组 400 人开始时间: 2005年5月18日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.EUCTR2004-002453-31-SEActelion Pharmaceuticals Ltd.400
进行中（未招募）
1 期
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhageEUCTR2004-002453-31-ATActelion Pharmaceuticals Ltd.400
进行中（未招募）
不适用
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhageEUCTR2004-002453-31-FIActelion Pharmaceuticals Ltd.400
进行中（未招募）
不适用
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist. - CONSCIOUS-1Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhageEUCTR2004-002453-31-BEActelion Pharmaceuticals Ltd.400
进行中（未招募）
不适用
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhageEUCTR2004-002453-31-DEActelion Pharmaceuticals Ltd.400